Cytotoxicity of Platinum and Palladium Chelates against Osteosarcoma

authors	Martins, AS; de Carvalho, ALMB; Lamego, I; Marques, PM; Gil, AM
nationality	International
journal	CHEMISTRYSELECT
author keywords	Cytotoxicity; Metal Chelates; Osteosarcoma; Palladium; Platinum
keywords	CISPLATIN RESISTANCE; BIOGENIC POLYAMINES; METAL-COMPLEXES; CELLS; PATHWAY; DRUGS; APOPTOSIS; IMPACT; NMR
abstract	This work reports the half maximal inhibitory concentrations, IC50, for conventional anti-cancer drug oxaliplatin (OXA) and potential new drugs Pt(2)Cl(2)Spm (Pt(2)Spm) and Pd(2)Cl(2)Spm (Pd(2)Spm) (Spm=Spermine) against osteosarcoma (OS). IC50 values provided by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Alamar Blue (AB) viability assays and cell density Sulforhodamine B (SRB) test were compared. Values obtained with MTT and AB were generally in agreement, and a tendency for lower IC50 values was noted by SRB, for OXA and Pd(2)Spm. The relative suitability of different assays is discussed for each chelate. The IC50 trend: cisplatin (cDDP)approximate to Pd(2)Spm
publisher	WILEY-V C H VERLAG GMBH
issn	2365-6549
year published	2020
volume	5
issue	20
beginning page	5993
ending page	6000
digital object identifier (doi)	10.1002/slct.202001361
web of science category	Chemistry, Multidisciplinary
subject category	Chemistry
unique article identifier	WOS:000536716700021